SCI REP:血浆IL-23和IL-5作为肝泡状棘球蚴病患者病变代谢活性的替代标记物!

2018-03-13 xing.T MedSci原创

由此可见,该研究为AE患者提供了一个新的可替代FDG-PET评估疾病进展的随访工具。

泡状棘球蚴病(AE)肝脏病变部位摄取的氟脱氧葡萄糖(FDG)是其代谢活性和疾病进展的信号。近日,Scientific reports杂志上发表了一篇研究文章,为了找到这个状态的替代标记物,研究人员在包含了30例AE患者和22名健康对照者的前瞻性病例对照研究中调查了外周和/或寄生部位周边免疫反应参数是否与代谢活动有关。

研究人员检测了伴有(MAAE)和无(MIAE)代谢活跃病变患者血浆和外周细胞中,以及MAAE患者肝脏中18个细胞因子和趋化因子水平,它们代表了先天性免疫和适应性免疫反应。

研究人员发现AE患者外周血中存在混合的细胞因子分布,以Th2、Th17和Treg细胞反应为主。检测到的标记中只有血浆IL-5和IL-23在MAAE患者中升高。采用IL-23区分MAAE和MIAE的能力在与IL-5结合使用时得到了明显的改善。IL-5和IL-23组合水平升高与PET扫描上FDG摄取显著相关。

由此可见,该研究为AE患者提供了一个新的可替代FDG-PET评估疾病进展的随访工具。

原始出处:

Tuerhongjiang Tuxun,et al. Plasma IL-23 and IL-5 as surrogate markers of lesion metabolic activity in patients with hepatic alveolar echinococcosis.Scientific reports.2018. https://www.nature.com/articles/s41598-018-20301-8

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1904503, encodeId=7374190450341, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Feb 14 13:02:00 CST 2019, time=2019-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479642, encodeId=133814e96425c, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Thu Mar 15 12:02:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626033, encodeId=48b616260331a, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Thu Mar 15 12:02:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296058, encodeId=49bb296058fb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Wed Mar 14 07:13:39 CST 2018, time=2018-03-14, status=1, ipAttribution=)]
    2019-02-14 wjywjy
  2. [GetPortalCommentsPageByObjectIdResponse(id=1904503, encodeId=7374190450341, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Feb 14 13:02:00 CST 2019, time=2019-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479642, encodeId=133814e96425c, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Thu Mar 15 12:02:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626033, encodeId=48b616260331a, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Thu Mar 15 12:02:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296058, encodeId=49bb296058fb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Wed Mar 14 07:13:39 CST 2018, time=2018-03-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1904503, encodeId=7374190450341, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Feb 14 13:02:00 CST 2019, time=2019-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479642, encodeId=133814e96425c, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Thu Mar 15 12:02:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626033, encodeId=48b616260331a, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Thu Mar 15 12:02:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296058, encodeId=49bb296058fb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Wed Mar 14 07:13:39 CST 2018, time=2018-03-14, status=1, ipAttribution=)]
    2018-03-15 tomyang93
  4. [GetPortalCommentsPageByObjectIdResponse(id=1904503, encodeId=7374190450341, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Feb 14 13:02:00 CST 2019, time=2019-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479642, encodeId=133814e96425c, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Thu Mar 15 12:02:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626033, encodeId=48b616260331a, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Thu Mar 15 12:02:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296058, encodeId=49bb296058fb, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Wed Mar 14 07:13:39 CST 2018, time=2018-03-14, status=1, ipAttribution=)]
    2018-03-14 yfjms

    学习

    0

相关资讯

强生向美国FDA提交重磅抗炎药Stelara补充生物制品许可(sBLA),治疗青少年斑块型银屑病

美国医药巨头强生(JNJ)近日宣布已向美国食品和药物管理局(FDA)提交了抗炎药Stelara(ustekinumab)的补充生物制品许可(sBLA),寻求批准用于青少年(12-17岁)中度至重度斑块型银屑病(plaque psoriasis)的治疗。据估计,在美国有750万人受斑块型银屑病困扰,其中大约三分之一在20岁以下。Stelara是一种单克隆抗体药物,靶向白细胞介素12(IL-12)和白

NEJM:IL-12和IL-23阻断可以有效的缓解白细胞粘附缺陷1型症状

阻断IL-12和IL-23可以有效的缓解白细胞粘附缺陷1型症状

DRUGS:Guselkumab获得首次全球认证

近日,美国强生研发的Guselkumab(Tremfya)已经获得美国FDA的上市审核用以治疗块型银屑病和银屑病型关节炎。和传统靶向TNF的抗炎抗体相比,Guselkumab特异性地作用于全新靶点白细胞介素(IL)-23。IL-23在辅助性T 细胞17(Th-17)的分化和增殖以及由其产生的包括IL-17和IL-22在内的促炎性细胞因子中起着关键作用。Th-17 / IL-17通路在抵御细菌和真菌

Lancet:单克隆抗体risankizumab用于克罗恩病

risankizumab较安慰剂对克罗恩病的临床缓解更为有效,选择性的抑制P19亚基可能是一种阻断IL-23治疗克罗恩病的有效途径

Nature:单克隆抗体Tildrakizumab对牛皮癣可能有效

                                              近日,来自奥地利的科学家们在著名国际期刊nature在线发表了他们的最新研